MedPath

ATX-101

Generic Name
ATX-101
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Background

ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. This includes treatment of superficial lipomas (benign tumors of soft tissue composed of mature fat cells), fat deposits in the submental region of the face/neck, and localized fat deposits in other parts of the body. Deoxycholic acid is a naturally occurring bile acid produced by the liver as one of several end products of cholesterol metabolism. As a naturally occurring component of the human body, deoxycholate is considered a ‘biocompatible’ detergent that solubilizes fat in the small intestine. ATX-101 demonstrates a relative selectivity for fat over other tissues.

Indication

Investigated for use/treatment in solid tumors.

Associated Conditions
-
Associated Therapies
-

Study Assessing Pain Relief After Replacement of the Knee

Phase 2
Terminated
Conditions
Acute Postoperative Pain
Interventions
First Posted Date
2022-03-02
Last Posted Date
2025-01-09
Lead Sponsor
Allay Therapeutics, Inc.
Target Recruit Count
112
Registration Number
NCT05260008
Locations
🇦🇺

John Flynn Private Hospital, Tugun, Queensland, Australia

🇦🇺

The Avenue Private Hospital, Windsor, Victoria, Australia

🇨🇦

Durham Bone and Joint Specialists, Ajax, Ontario, Canada

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath